Chinese firm injects thousands with experimental corona vaccine
Published : Saturday, 12 September, 2020 at 4:31 PM Count : 261
Chinese pharmaceutical firm has injected hundreds of thousands with one of two experimental vaccines for coronavirus disease, or COVID-19, The Wall Street Journal reported Friday quoting the company.
China National Biotec Group Co., a subsidiary of state-owned Sinopharm, has given the unproven inoculations under an emergency program approved by China in July, the Journal said. In a separate report Friday by Bloomberg, CNBG and other Chinese vaccine developers emphasized the safety of their medication.
The report follows others in which a separate Chinese company, Sinovac Biotech, reported at a trade fair in Beijing last week that it, too, had injected between 2,000 and 3,000 of its employees and family members with its experimental vaccine.
The potential vaccines are two of about 35 candidates being developed around the world, Bloomberg reported, and are still undergoing Phase 3 clinical trials. The revelations of its relative widespread use come at a time when Democrats have accused the Trump administration of rushing the development of vaccines by American manufacturers and pressuring the FDA to approve them.
In August, Russia announced it had successfully developed its vaccine.
The Chinese government gave the OK for its military members to receive an experimental vaccine developed by CanSino Biologics in June, and then authorized broader use for medical workers a month later.
CNBG’s Zhou Song said via the company’s social-media account that no one who received the inoculation had become infected with the SARS-CoV-2 virus that causes the respiratory affliction COVID-19 nor experienced any obvious adverse reactions.
The three vaccine candidates are still undergoing Phase 3 clinical trials, which involve testing a vaccine’s safety and effectiveness on thousands of people. Six other leading Covid-19 vaccine candidates are also in this final phase, according to the World Health Organization.
Regulators in individual countries usually determine whether to let the broader public use a vaccine only after its testing is complete. The U.S., U.K. and Germany, where some of the leading candidates originate, haven’t yet approved any Covid-19 vaccine for use outside of clinical trials.